metabolic dysfunction-associated steatohepatitis
Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials
Efimosfermin alfa (BOS-580), Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic steatohepatitis (NASH), Phase 2 clinical trials, FGF21 analogue, Liver disease treatment, Pivotal trials
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical
Aligos Therapeutics Reports Positive Phase IIa Results for MASH Treatment, Despite Investor Skepticism
Aligos Therapeutics, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase IIa trial, ALG-055009, Liver fat reduction, Investor skepticism, Placebo effect
FDA Grants Accelerated Approval to Madrigal’s Rezdiffra for MASH Treatment
FDA approval, Madrigal Pharmaceuticals, Rezdiffra (resmetirom), Metabolic dysfunction-associated steatohepatitis (MASH), Accelerated clearance, Adult patients with non-cirrhotic MASH and moderate-to-advanced liver fibrosis
Akero Reinforces Phase III FGF21 Analog Candidate with Enhanced Fibrosis Response Rates in MASH Data Update
Akero Therapeutics, FGF21 Analog, efruxifermin (EFX), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Phase IIb HARMONY Study, Fibrosis Response Rate, 96 Weeks, Statistically Significant Improvements